Kornimate/medical-research-clean huggingface dataset:
validity and reliability of the dutch hdi

Conditions: Headache; Headache Disorders; Neck Pain; Cervical Pain

Summary: the aim of our study is to investigate the validity and reliability of dutch version of the henry ford hospital headache disability questionnaire (hdi).

there is only a limited number of questionnaires that map headache-related disability. to gain a better understanding of the emotional and functional effects of headaches on the patient's well-being, an english questionnaire already exists: the henry ford headache disability index (hdi). the purpose of the hdi is to map headache related disabiltiy. this 25-item questionnaire focusses on two categories; there are 13 questions in the field of emotional effects and 12 questions on functional effects of headache complaints. advantage: this questionnaire can be used for all headache patients, in contrast to many questionnaires that can only be used for migraine patients. (eg midas, migraine act, id migraine...) the questionnaire contains more items than the headache impact test (hit-6), consisting of 6 items. the questions are very specifically aimed at headaches and can also be used to further inquire about the anamnesis after completing the questionnaire. problem statement: there is no validated dutch version yet. objective: to translate and validate a dutch version of the hdi. about 250 patients with chronic headache will be recruited to determine the validity (face validity, content validity, convergent validity with the rand-36 and hit-6). in addition, internal consistency and short- and long-term test and retest reliability will be evaluated using the intraclass correlation coefficient (icc).

Eligibility criteria:
inclusion criteria: * patients with primary or secondary headache, diagnosed by a neurologist according to the ichd-3 classification. * at least 1 day of headache in the previous month. * native dutch speaking participants exclusion criteria: * all other headache types not classified by the ichd-3 as primary or secondary headache. * secondary headache in combination with underlying pathological situations (infection, trauma, tumors, brain haemorrhages) or severe psychotic or mental dysfunctions or substance use/withdrawal symptoms.
compassionate treatment : an exploratory clinical trial to assess treatment of amyotrophic lateral sclerosis

Conditions: Amyotrophic Lateral Sclerosis

Summary: the purpose of the study is to determine the safety and possible effectiveness of autologous adipose-tissue derived stem cells treatment in a amyotrophic lateral sclerosis(als) patient.

this pilot clinical trial is design to see the safety and possible efficiency of adscs treatment in a als patient. one subjects will be treated (n=1). the patient will receive brain transplantation of adscs and combines intravenous infusion adscs 4 times. subjects will be assessed by adverse effects and functional outcomes of clinical: pi max , pe max,and haloscale respiration, als functional rating scale (als-frs) are analyzed at 1 month, 3 months, 6 months 9 months and 12 months. brain mri scans will be obtained before and after the treatment. long term follow-up will be performed at 1, 6 , and 12months for safety reasons. brain ct for check operation safety before and after brain implantation. timing of study: 12months recruitment period after approvals

Eligibility criteria:
compassionate treatment the number of participants for a person. the patients (guo xx) of 28% of lung function assessment (normal lung function was greater than 80%), the daily life of motor function score was 17 points (normal function score of 40 points).

Keywords: amyotrophic lateral sclerosis autologous adipose-tissue derived stem cells (adscs)
health-promoting lifestyle in a genetic counseling clinic

Conditions: Breast Cancer; Genetic Testing

Summary: this was a cross-sethis was a cross-sectional study, which aimed to describe the health-promoting lifestyle of breast cancer patients and family members in a chinese genetic counseling clinic, and to explore its various levels with different socio-economic variables. 259 patients conformed to the inclusion and exclusion criteria were enrolled. participants were sent a questionnaire web-link to be invited to finish this survey. 140 participants were finally included in this study. finally, a good level of health-promoting lifestyle of breast cancer patients and family members was acquired. more education and intervention should be tailored to enhance and encourage health-promoting lifestyle behaviors in participants with low monthly family income. additionally, developing nutritional curriculum and strengthening the publicity of nutritional popular science were priorities in the future improvement measures.ctional study

purpose: this study aimed to describe the health-promoting lifestyle of breast cancer patients and family members in a chinese genetic counseling clinic, and to explore its various levels with different socio-economic variables. method: this was a cross-sectional study. the participants in this study originated from a genetic counseling clinic of a cancer center in shanghai, china. 259 patients conformed to the inclusion and exclusion criteria were screened and contact from november 2019 to march 2022. participants agreed to participate were sent a questionnaire web-link to be invited to finish this survey. two questionnaires were included in the link, one referring to the socio-economic information, the other referring to the health-promoting lifestyle. chinese health-promoting lifestyle profile-ⅱ(hplp-ⅱ) was used to evaluate the health-promoting lifestyle.

Eligibility criteria:
inclusion criteria: * over 18 years old; * with a diagnosis of breast cancer or having a family history of breast cancer * the first time to take genetic testing in our clinic * ecog\<2. exclusion criteria: * diagnosed with psychiatric or intellectual impairment * having a history of genetic testing previously

Keywords: health-promoting lifestyle, breast cancer, genetic
role of piwi-protein interacting rna, mirna-194 and amino acids in patients with prostate cancer

Conditions: Finding New Biomarkers That Could be Evaluated in Patients With Prostate Cancer and Clarify Their Role in Early Detection of Prostate Cancer

Summary: prostate cancer is one of the most frequently diagnosed cancers and one of the main causes of death due to tumors in men . the mechanisms of its carcinogenesis have not been fully elucidated yet . prostate tumours remain undetected or dormant for a long period of time before they progress loco-regionally or at distant sites as overt tumours. the molecular mechanism of dormancy is yet poorly understood

currently, early detection of prostate cancer involves mainly digital rectal examination (dre) and testing of prostate-specific antigen (psa) level in blood . however, over the years it became clear that psa is not a specific biomarker of prostate cancer . finding out new biomarkers is pivotal for early detection of prostate cancer, increasing the accuracy of diagnosis, and reducing the false positives in psa testing these biomarkers include many biological compounds such as, micrornas, small nuclear rnas (sncrna), proteins and metabolites . piwi-interacting rnas (pirnas), a class of sncrna molecules, are associated with the piwi proteins. moreover, micrornas (mirnas) are conserved small non-coding rnas (19-22 nucleotide-long) that mediate post-transcriptional regulation of gene expression, affecting mrna stability and translation by binding complementary sites on target mrnas\[15\]. studies have shown that the mirnas have critical roles in a variety of biological processes such as: cell proliferation, differentiation, apoptosis and carcinogenesis. regucalcin (rgn) is an inhibitory protein of calcium signaling with calcium-binding properties. it plays a multifunctional role in the regulation of cell functions. free amino acids, in biological fluids can be a reduced invasive method associated to a high diagnostic potential. it was found that free amino acid profiles vary depending on type of cancer and its stage.

Eligibility criteria:
inclusion criteria: * • patients who are confirmed to have prostate cancer or benign prostatic hyperplasia based on digital rectal examination (dre), trasrectal ultrasonography and histopathological examination of biopsy tissue * the control group consisted of healthy men with no cancer and no chronic diseases. they will be age-matched with patient group and recruited among men subjected to the routine periodic medical examination. exclusion criteria: * • other coexisting cancers, * prostate cancer treatment
diagnostic performance of clinical signs patients suspected of meningitis to emergencies

Conditions: Meningitis

Summary: meningitis are serious infections. evidenced by high rates of mortality and sequelae. however, these diseases have a relatively small impact. also physician services home emergencies they must be vigilant, alert, for clinical signs to be suspected meningitis. indeed, it is only after this essential clinical milestone that will be carried out a lumbar puncture which will confirm the diagnosis and to quickly begin treatment. unfortunately, if recent studies can improve the therapeutic management of patients with meningitis, no study was interested in yet fundamental step of diagnosis. it seems therefore necessary to achieve a prospective clinical study to reassess the adequacy of the clinical signs in the diagnosis of meningitis. the ideal would be to achieve a predictive clinical score of the presence or absence of meningitis.


Eligibility criteria:
inclusion criteria: may be included in the study two groups of patients: \*on the one hand, those in which will be carried out a lumbar puncture. ideally, all patients in whom the examination is envisaged will be included. the logistics must allow inclusion rate as high as possible (see below). so, are included in this group, patients for which the following criteria are met: * over 15 years patient and 3 months, * admission to the emergency for less than 6 hours * realization of a proposed lumbar puncture, * information sheet given. \*on the other hand, those in whom it is not intended to be carried by lumbar puncture, but for which the clinical picture present on admission makes relevant for clinical signs of meningitis. so, are included in this group, patients for which the following criteria are met: * over 15 years patient and 3 months, * admission to the emergency for less than 6 hours * at least one of the following 5 clinical signs motivating consultation and / or present on admission: * fever (measured temperature above 38 ° c) * headache, * vomiting, * stiff neck, * vigilance disorders, * information sheet given. exclusion criteria: * patient who underwent neurosurgery recent (within the month before admission).
flat dose vs. weight-based ip chemotherapy for crs/hipec

Conditions: Peritoneal Carcinomatosis

Summary: peritoneal carcinomatosis from advanced gastro-intestinal malignancy has historically been associated with poor overall survival (≤ 12 months) with few treatment options. cytoreductive surgery (crs), which involves removal of all macroscopic tumor nodules, combined with direct administration of heated intra-peritoneal (ip) chemotherapy (hipec) to the affected peritoneal surfaces, has been shown to be an effective treatment option that extends overall survival among certain cases of peritoneal carcinomatosis. ip chemotherapy allows delivery of a high dose of cytostatic drug directly onto the peritoneal surfaces at risk for microscopic residual disease while systemic exposure remains limited. additionally, hyperthermia is known to enhance the cytotoxicity of several agents (including mitomycin c) and improves the depth of peritoneal penetration. this trial will be a randomized phase 2 comparison of flat dose versus weight-based dose mitomycin c. the hypothesis of this study is that hipec weight-based dosing may result in similarly effective peritoneal mitomycin c concentrations with less systemic absorption and potential systemic toxicity, compared with the hipec flat dosing approach in patients undergoing crs/hipec.


Eligibility criteria:
inclusion criteria: * patients diagnosed with one of the following: low-grade appendiceal mucinous neoplasm, appendiceal cancer with peritoneal carcinomatosis, colorectal cancer with peritoneal carcinomatosis * ecog performance status \< 3 * candidate for grossly complete cytoreductive surgery * life expectancy greater than 3 months * adequate organ and marrow function * ability to understand and the willingness to sign a written informed consent document exclusion criteria: * any extra-abdominal metastases * untreated lung metastases * liver metastases not amenable to resection or ablation * known brain metastases * chemotherapy or radiotherapy within 4 weeks prior to entering the study * presence of residual significant adverse events attributed to prior cancer treatment * currently receiving any other investigational therapeutic agents * history of allergic reactions attributed to compounds of similar chemical or biologic composition to mitomycin c. * pregnant or breast-feeding women * uncontrolled ongoing illness

Keywords: cytoreductive surgery colorectal cancer pseudomyxoma peritonei appendiceal mucinous neoplasm mitomycin c pharmacokinetics crs/hipec hipec appendix cancer lamn
virtual reality (vr) tour to reduce preoperative anxiety before anaesthesia

Conditions: Anaesthesia; Anxiety; Postoperative Pain

Summary: anxiety and apprehension are common among patients prior to surgery. this anxiety can lead to additional discomfort, increased pain sensation and increased stress symptoms. virtual exposure has proven to be successful in exposure therapy for the treatment of the narrowest patients. patients are not confronted with the real stimuli or situations that trigger the branches, but with virtual representations of them. virtual reality (vr) makes it possible to create scenarios that would not be possible in reality because of the organisational, time or financial expenditure involved.the effectiveness of virtual stimulus exposure is well documented, especially in the case of object or situation-related fears in the context of specific phobias. it is therefore obvious that virtual stimulus exposure could also be suitable for minimising operation-associated fears.the research project described is designed to investigate the effect of virtual stimulus exposure on perioperative anxiety. for this purpose, a virtual tour of the operating setting has been created, which enables patients to explore the surroundings in detail by means of vr glasses.

anxiety and apprehension are common among patients prior to surgery. this anxiety can lead to additional discomfort, increased pain sensation and increased stress symptoms. virtual exposure has proven to be successful in exposure therapy for the treatment of the narrowest patients. patients are not confronted with the real stimuli or situations that trigger the branches, but with virtual representations of them. virtual reality (vr) makes it possible to create scenarios that would not be possible in reality because of the organisational, time or financial expenditure involved.the effectiveness of virtual stimulus exposure is well documented, especially in the case of object or situation-related fears in the context of specific phobias. it is therefore obvious that virtual stimulus exposure could also be suitable for minimising operation-associated fears.the research project described is designed to investigate the effect of virtual stimulus exposure on perioperative anxiety. for this purpose, a virtual tour of the operating setting has been created, which enables patients to explore the surroundings in detail by means of vr glasses.

Eligibility criteria:
inclusion criteria: * all patient undergoing anaesthesia without the following exclusion criteria exclusion criteria: * \< 18 years * cancer surgery * pregnancy * postoperative setting icu * neurosurgery * thorax surgery

Keywords: virtual reality (vr) anxiety preoperative opearting theater
cart-19 t cell in cd19 positive relapsed or refractory acute myeloid leukemia (aml)

Conditions: Acute Myeloid Leukemia

Summary: this is a single center, open-label phase 1/2 study to evaluate the safety and efficacy of targeted cd19 chimeric antigen receptor engineered t cell immunotherapy (cart) in the treatment of cd19 positive relapsed or refractory acute myeloid leukemia.

the patients will receive infusion of cart cells targeting cd19 to confirm the safety and efficacy of cd19 cart cells in relapsed or refractory acute myeloid leukemia.

Eligibility criteria:
inclusion criteria: * male or female patients with cd19+ relapsed/refractory acute myeloid leukemia * age 6-65 years. * left ventricular ejection fractions≥ 0.5 by echocardiography. * creatinine \< 1.6 mg/dl. * aspartate aminotransferase/aspartate aminotransferase \< 3x upper limit of normal. * bilirubin \<2.0 mg/dl. * karnofsky performance status ≥ 60 * expected survival time ≥ 3 months (according to investigator's judgement) exclusion criteria: * pregnant or lactating women. * uncontrolled active infection. * active hepatitis b or hepatitis c infection. * class iii/iv cardiovascular disability according to the new york heart association classification. * hiv infection. * patients with history of seizure * active central nervous system leukemia
the use of pycnogenol® to alleviate menopausal symptoms induced or increased by breast and gynecological cancer treatments

Conditions: Climacteric; Menorrhagia, Menopausal; Menopause

Summary: this is a pilot study to test whether pyc can improve climacteric symptoms for women who have experienced either surgically or medically induced menopause as part of their treatment for breast or gynecologic cancers.


Eligibility criteria:
inclusion criteria: * patient currently is undergoing treatment for cancer * patient has menopausal symptoms induced either by surgical or medical (patient on tamoxifen or aromatase inhibitor) interventions for cancer * \> 18 years of age * willing to travel to a legacy health facility if necessary * agree to attend study visits outside of standard of care visits, if needed * willing to stop other supplements or medications that are aimed at treating menopausal symptoms at least 7 days before beginning study treatment * willing to engage in pre/post testing and survey/phone calls exclusion criteria: * patient is currently undergoing chemotherapy treatment * \< 18 years of age * unable to comply with protocol * unable to provide written informed consent * investigator does not believe study participation is in the best interest of the patient * patient had concurrent menopausal symptoms prior to the start of cancer treatment * menopausal symptoms are unrelated to surgical or medical treatment of breast or gynecologic cancers
cilostazol in acute ischemic stroke treatment (caist)

Conditions: Cerebral Infarction

Summary: the purpose of this study is to study efficacy and safety of cilostazol use in patients with acute ischemic stroke.

stroke is a leading cause of death and elderly disability in developed countries. however, treatment of acute stroke is limited except thrombolytic therapy in hyperacute stroke within several hours. currently, aspirin is widely used in spite of its small benefit compared to bleeding complications. cilostazol will be compared to aspirin in acute stroke patients in terms of functional outcome at 3 months, efficacy to prevent stroke recurrence, and safety for bleeding complications.

Eligibility criteria:
inclusion criteria: * patients who receive explanation on this study and give informed consent * patients aged 30 to 85 years * baseline nihss less than 15 * onset of symptoms within 48 hours of the start of investigational product * full functional independence prior to the present stroke indicated by an mrs score of 0, 1, 2 exclusion criteria: * evidence from ct or mri scan of an acute intracranial hemorrhage, a tumor, encephalitis or any diagnosis other than acute ischemic stroke likely to cause the present symptoms. * previous regular use of an antiplatelet agent or warfarin * patients with known cardiac disease likely to cause cardiogenic embolism or congestive heart failure * evidence from ct or mri scan of midline shift when visiting hospital * uncontrolled hypertension (sbp\>220 mmhg or dbp\>120 mmhg) * hypotension (\<90/60 mmhg) * patients with known bleeding diathesis or coagulation disorder * patients with liver disease (alt\>100 or ast\>100), or renal disease (creatinine\>2.0 mg/dl) * known severe anaemia (hemoglobin\<8.0 mg/dl), or thrombocytopenia (platelet\<100,000/mm3) * scheduled for endarterectomy within 3 months * severe co-morbidity likely to limit patient's life expectancy to less than 6 months * patients with alcohol or illegal drug abuse or dependency * pregnant or lactating patients. when administrating to females, it should be confirmed that the patients is in the menopause (by evaluation of investigators) or permanently infertile (hysterectomy or surgical operation like bilateral tubal ligation, bilateral oophorectomy, etc). if a patient is likely to be pregnant, the patient should not be pregnant before randomization. and, the patient should use reliable contraception between at least 3 weeks before randomization to 7 days after the final administration of study drug. * patients treated by thrombolytic agents like tpa after onset of stroke

Keywords: cilostazol aspirin cerebral infarction
noninvasive skin spectroscopy for diabetes screening

Conditions: Prediabetic State; Diabetes Mellitus, Type 2

Summary: the objective of this study is to assess the performance of a noninvasive device for the early screening of diabetes mellitus.

approximately 18 million people have type ii diabetes, and of these, an estimated thirty-five percent are unaware of their condition. this translates to roughly 6.3 million undiagnosed cases worldwide in 2002. many diagnoses are made years after the onset of the disease. this allows progression of the vascular lesions that arise during the time of uncontrolled glucose levels. as a result, microvascular retinopathy, nephropathy, and neuropathy are on the rise, as well as macrovascular complications such as: coronary heart disease, and cerebral vascular accidents. the prevalence and trends of diabetes underscore the need for effective and widespread screening. our fluorescence based system under development will noninvasively measure skin glycation end products that are known to be strongly correlated with diabetes status and complications. since the test would be painless and require no patient fasting, significant obstacles to screening compliance would be mitigated. the system offers hope for a screening test that is more sensitive and specific than the invasive tests currently used for diabetes screening (oral glucose tolerance test (ogtt) and the fasting plasma glucose (fpg) test).

Eligibility criteria:
inclusion criteria: * volunteers without diabetes. * volunteers at risk for developing type ii diabetes. * 18 years of age and older. exclusion criteria: * under 18 years of age. * those diagnosed with diabetes.